BioSpace News Archive

SCHOTT continues to produce record-breaking numbers of pharmaceutical containers, including critical glass vials, as the U.S. prepares for COVID-19 vaccine distribution.

Interim DESTINY-Lung01 research data from the HER2 overexpressing metastatic non-small cell lung cancer (NSCLC) cohort of ENHERTU ® will be featured as late-breaker presentation Updated TROPION-PanTumor01 results of datopotamab deruxtecan in patients with advanced NSCLC to be highlighted Biomarker analysis from phase 1 trial of patritumab deruxtecan in patients with previously treated metastatic or locally advanced EGFR

Breakthrough Data on Predicting Immuno-Oncology Treatment Response, Additional Partnerships, and Pending Launch of Ovarian Cancer Test Expand Opportunities in 2021 and Beyond

-- Alliance will assess the use of Sarepta’s proprietary gene editing technology and Genevant’s proprietary LNP delivery platform for multiple neuromuscular targets -- -- Sarepta to have options for an exclusive license to Genevant’s LNP technology for four neuromuscular indications -- -- Genevant may receive approximately $50 million in near-term payments and is also eligible for significant future milestones and royalties --

Milestone payment triggered by acceptance for review of a BLA for V114, an investigational 15-valent pneumococcal conjugate vaccine that utilizes Ligand’s CRM197 carrier protein

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediated dermatological diseases and conditions, today announced that it has commenced pivotal Phase 3 clinical trials evaluating topical roflumilast cream (ARQ-151) as a potential treatment for atopic dermatitis (AD)

BeiGene, Ltd., a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration for use in combination with two chemotherapy regimens as a first-line treatment for patients with advanced squamous non-small cell lung cancer.